Prostate Cancer Foundation - Accomplishments

Accomplishments

Through the Prostate Cancer Foundation's unique funding structure, PCF funding has been a major part of some of the most significant discoveries in the field of prostate cancer research. These discoveries and advancements include:

• supported research for new life prolonging treatments for advanced metastatic prostate cancer:
  • Xtandi (MDV3100) - FDA Approved
  • Zytiga (abiraterone) - FDA Approved
  • Xgeva (denosumab) - FDA Approved
  • Provenge (sipuleucel-T) - FDA Approved

• supported research of 97 drugs in Phase I or II trials, and 3 more PCF-supported therapeutics are rapidly working their way through Phase III clinical trials:
  • Alpharadin
  • Ipilimumab
  • XL184
• identification of 27+ varieties (genotypes) of prostate cancer
• support of clinical trials through the Prostate Cancer Clinical Trials Consortium at 13 centers in the U.S., enrolling more than 3,200 patients; today supporting 38 active trials
• development of genetic testing of men at highest risk of prostate cancer
• research into stopping the production or function of growth factors that help cancer cells grow
• research concerning anti-angiogenesis
• determination of the structure of the prostate cell androgen receptor, which is responsible for the growth of both normal and cancerous prostate cells;
• identification of prostate cell surface markers that can be targeted to destroy cancer cells
• development of analytical methods that identify the proteins in blood or the prostate that correlate to treatment effect or behavior of the cancer cell, a method known as proteomic pattern recognition.